Loading...
Market
Story
Alumis Announces $316 Million IPO, Seeks $1 Billion Valuation
Jun 24, 2024, 02:50 PM
Alumis, an immunology biotech company, has announced its initial public offering (IPO) of 17.65 million shares priced between $16 and $18 per share. The company aims to raise $300 million through this IPO, which will support its TYK2 inhibitor through phase 3 psoriasis trials. Alumis is seeking a valuation of up to $1 billion in the US market. The proceeds from the planned IPO, tagged at $316 million, will also help fund a late-stage clinical trial for psoriasis.
View original story
Similar markets
Completed successfully • 33%
Ongoing • 34%
Terminated • 33%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial discontinued • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%